info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Esophageal Cancer Companies

Esophageal cancer is a type of malignancy that affects the esophagus, the tube that connects the throat to the stomach. Various companies are actively involved in the development of diagnostic tools, treatments, and therapeutic interventions for esophageal cancer.

Esophageal Cancer Key Companies

 

Latest Esophageal Cancer Companies Update


Dec 2023Henlius Biotech (China) Received NMPA approval for HANSIZHUANG (serplulimab), an anti-PD-1 monoclonal antibody, in combination with fluorouracil and platinum for first-line treatment of PD-L1 positive unresectable locally advanced, recurrent or metastatic ESCC.Partnered with leading cancer centers in China and other regions to conduct clinical trials for their pipeline of esophageal cancer drugs.


AstraZeneca (UK) Received FDA Breakthrough Therapy Designation for Imfinzi® (durvalumab) in combination with chemotherapy for unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after first-line therapy.Launched awareness campaigns and educational initiatives to improve early diagnosis and access to treatment for esophageal cancer.


Boehringer Ingelheim (Germany) Presented positive Phase 2 data for their novel JNK/TGF-beta-targeted therapy BIB104 in patients with advanced esophageal cancer, paving the way for further clinical development.Collaborated with academic institutions and clinical research organizations to explore innovative treatment approaches for esophageal cancer.


Johnson & Johnson (US) Announced positive Phase 3 results for their PD-1 inhibitor Tremfya® (guselkumab) in combination with chemotherapy for locally advanced or metastatic esophageal cancer, suggesting potential for improved survival rates.Invested in research and development of next-generation immunotherapy drugs with tailored target specificity for enhancing efficacy and reducing side effects.


Esai (Japan) Developed a new AI-powered system for analyzing endoscopic images to assist in early detection of esophageal cancer and improve diagnostic accuracy.Partnered with technology companies to develop advanced diagnostic tools and personalized treatment platforms for esophageal cancer patients.


List of Esophageal Cancer Key Companies in the Market



  • Amgen

  • Eli Lilly and Company

  • Hoffmann-La Roche

  • Bristol-Myers Squibb Company

  • Boehringer Ingelheim GmbH

  • Bristol-Myers Squibb

  • GlaxoSmithKline Plc.

  • Novartis AG

  • Johnson & Johnson

  • Gilead Sciences

  • Merck & Co.


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.